Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 4, 2003, Pages 915-928

  Kuban, Deborah A ^a,j   Thames, Howard D ^a   Levy, Larry B ^a   Horwitz, Eric M ^b   Kupelian, Patrick A ^c   Martinez, Alvaro A ^d   Michalski, Jeff M ^e   Pisansky, Thomas M ^f   Sandler, Howard M ^g   Shipley, William U ^h   Zelefsky, Michael J ⁱ   Zietman, Anthony L ^h  

^a UNIVERSITY OF TEXAS   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Long term outcome; Multi institutional analysis; Prostate cancer; Radiotherapy

Indexed keywords

ANTIGENS; HORMONES; RADIOTHERAPY; TUMORS;

HORMONAL THERAPY;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0142186677     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00632-1     Document Type: Article

References (21)

1. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer A multi-institutional pooled analysis. JAMA. 281:1999;1598-1604.
2. Thames HD, Kuban DA, Levy LB, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancers treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003;57:929-943.
3. Consensus statement Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
4. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome following irradiation for clinically localized prostatic carcinoma. Cancer. 79:1997;337-344.
5. Kattan M.W., Zelefsky M.J., Kupelian P.A., et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 18:2000;3352-3359.
6. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy The 15-year Johns Hopkins experience. Urol Clin North Am. 28:2001;555-565.
7. Han M., Partin A.W., Piantadosi S., et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 166:2001;416-419.
8. Buchsbaum J., Elshaikh M., Kupelian P.A., et al. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy Year of treatment is an independent predictor of outcome. [Abstract] Int J Radiat Oncol Biol Phys. 51:(Suppl. 1):2001;169.
9. Jhaveri F., Kupelian P.A., Levin H., et al. Declining rates of extracapsular extension in radical prostatectomy Evidence of continued stage migration. J Clin Oncol. 17:1999;3167-3172.
10. Johnstone P.A., Riffengurgh R., Saunders E.L., et al. Grading inaccuracies in diagnostic biopsied revealing prostatic adenocarcinoma Implications for definitive radiation therapy. Int J Radiat Oncol Biol Phys. 32:1995;479-482.
11. D'Amico A.V., Chen M.H., Oh-Ung J., et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys. 54:2002;436-441.
12. Vicini F.A., Kestin L.L., Martinez A.A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 45:1999;553-561.
13. Kestin L.L., Vicini F.A., Martinez A.A. Practical application of biochemical failure definitions What to do and when to do it. Int J Radiat Oncol Biol Phys. 53:2002;304-315.
14. Amling C.L., Blute M.L., Bergstrath E.J., et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer Continued risk of biochemical failure after 5 years. J Urol. 164:2000;101-105.
15. Coen J.J., Zietman A.L., Thakral H., et al. Radical radiation for localized prostate cancer Local persistence of disease results in a late wave of metastases. J Clin Oncol. 20:2002;3199-3205.
16. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 53:2002;1097-1105.
17. Kuban D.A., Pollack A., Huang E., Levy L., et al. The hazards of dose escalation in prostate cancer radiation. [Abstract] Int J Radiat Oncol Biol Phys. 54:(Suppl. 2):2002;180.
18. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881.
19. Lyons J.A., Kupelian P.A., Mohan D.S., et al. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology. 55:2000;85-90.
20. Critz F.A. A standard definition of disease freedom is needed for prostate cancer Undetectable prostate specific antigen compared with the American Society for Therapeutic Radiology and Oncology consensus definition. J Urol. 167:2002;1310-1313.
21. Gretzer M.B., Trock B.J., Han M., et al. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol. 168:2002;1419-1422.